USA flag logo/image

An Official Website of the United States Government

HETEROANTISERA AGAINST INTERFERON (IFN) AND INTERLEUKIN-2 (IL-2) ARE HIGHLY…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
3050
Program Year/Program:
1985 / SBIR
Agency Tracking Number:
3050
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Genzyme Corp.
75 Kneeland St Boston, MA 02111
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1985
Title: HETEROANTISERA AGAINST INTERFERON (IFN) AND INTERLEUKIN-2 (IL-2) ARE HIGHLY IMMUNOSUPPRESSIVE WHEN INJECTED INTO EXPERIMENTAL ANIMALS.
Agency: HHS
Contract: N/A
Award Amount: $49,535.00
 

Abstract:

HETEROANTISERA AGAINST INTERFERON (IFN) AND INTERLEUKIN-2 (IL-2) ARE HIGHLY IMMUNOSUPPRESSIVE WHEN INJECTED INTO EXPERIMENTAL ANIMALS. THESE ANTICYTOKINES IMPAIR THE GENERATION OF CYTOLYTIC T CELLS, THE REJECTION OF TRANSPLANTED TUMORS, AND OTHER CELLULAR IMMUNE FUNCTIONS. MURINE MONOCLONAL ANTIBODIES AGAINST IL-2 HAVE BEEN AVAILABLE FOR SEVERAL YEARS, AND RECENTLY THE TECHNOLOGY FOR THE GENERATION OF HUMAN MONOCLONAL ANTIBODIES HAS EMERGED. PATIENTS TREATED WITH IFN IN VARIOUS CLINICAL TRIALS AND PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSIS WITH HIGH ENDOGENOUS LEVELS OF IFN DEVELOP ANTIBODIES AGAINST IFN. SIMILARLY, PATIENTS REPEATEDLY INJECTED WITH RECOMBINANT IL-2 AS TREATMENT FOR REFRACTORY CANCER DEVELOP IGG ANTIBODIES AGAINST IL-2. WE PROPOSE TO GENERATE HUMAN HYBRIDOMAS FROM THE B-LYMPHOCYTES OF THESE PATIENTS BY FUSION WITH HUMAN MYELOMA CELL LINES. THE CULTURE SUPERNATANTS OF THESE HYBRIDOMAS WILL BE SCREENED FOR ANTI-IL-2 ANTIBODIES WITH A SENSITIVE ELISA AND SUBSEQUENTLY FOR THE ABILITY TO INHIBIT IL-2-INDUCED T-CELL PROLIFERATION, CYTOLYTIC T-CELL INDUCTION, AND THE DEVELOPMENT OF A DELAYED-TYPE HYPERSENSITIVITY RESPONSE TO TUBERCULIN. THESE NEUTRALIZING ANTIBODIES MAY BE CLINICALLY USEFUL IN THE PREVENTION AND TREATMENT OF ORGAN ALLOGRAFT REJECTION AND IN THE

Principal Investigator:

Donald s. masters
PRINCIPAL INVESTIGATOR
6174511923

Business Contact:

Small Business Information at Submission:

Genzyme Corpon
75 Kneeland Street Boston, MA 02111

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No